Literature DB >> 29329455

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo.

Sabue Mulangu1,2, Vivian H Alfonso3, Nicole A Hoff3, Reena H Doshi3, Prime Mulembakani4, Neville K Kisalu1, Emile Okitolonda-Wemakoy4, Benoit Ilunga Kebela5, Hadar Marcus1, Joseph Shiloach6, Je-Nie Phue6, Linda L Wright7, Jean-Jacques Muyembe-Tamfum2, Nancy J Sullivan1, Anne W Rimoin3.   

Abstract

Background: Previous studies suggest that cases of Ebola virus disease (EVD) may go unreported because they are asymptomatic or unrecognized, but evidence is limited by study designs and sample size.
Methods: A large population-based survey was conducted (n = 3415) to assess animal exposures and behaviors associated with Ebolavirus antibody prevalence in rural Kasai Oriental province of the Democratic Republic of Congo (DRC). Fourteen villages were randomly selected and all healthy individuals ≥1 year of age were eligible.
Results: Overall, 11% of subjects tested positive for Zaire Ebolavirus (EBOV) immunoglobulin G antibodies. Odds of seropositivity were higher for study participants older than 15 years of age and for males. Those residing in Kole (closer to the outbreak site) tested positive at a rate 1.6× higher than Lomela, with seropositivity peaking at a site located between Kole and Lomela. Multivariate analyses of behaviors and animal exposures showed that visits to the forest or hunting and exposure to rodents or duikers predicted a higher likelihood of EBOV seropositivity. Conclusions: These results provide serologic evidence of Ebolavirus exposure in a population residing in non-EBOV outbreak locations in the DRC and define statistically significant activities and animal exposures that associate with EBOV seropositivity.
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Entities:  

Keywords:  Democratic Republic of the Congo; Ebola virus disease; Ebolavirus; serology; seroprevalence

Mesh:

Substances:

Year:  2018        PMID: 29329455      PMCID: PMC5853806          DOI: 10.1093/infdis/jix619

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Immunoglobulin G enzyme-linked immunosorbent assay using truncated nucleoproteins of Reston Ebola virus.

Authors:  T Ikegami; M Saijo; M Niikura; M E Miranda; A B Calaor; M Hernandez; D L Manalo; I Kurane; Y Yoshikawa; S Morikawa
Journal:  Epidemiol Infect       Date:  2003-06       Impact factor: 2.451

2.  Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography.

Authors:  Tanmay A M Bharat; Takeshi Noda; James D Riches; Verena Kraehling; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka; John A G Briggs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

Review 3.  Ecological dynamics of emerging bat virus spillover.

Authors:  Raina K Plowright; Peggy Eby; Peter J Hudson; Ina L Smith; David Westcott; Wayne L Bryden; Deborah Middleton; Peter A Reid; Rosemary A McFarlane; Gerardo Martin; Gary M Tabor; Lee F Skerratt; Dale L Anderson; Gary Crameri; David Quammen; David Jordan; Paul Freeman; Lin-Fa Wang; Jonathan H Epstein; Glenn A Marsh; Nina Y Kung; Hamish McCallum
Journal:  Proc Biol Sci       Date:  2015-01-07       Impact factor: 5.349

4.  Improved specificity of testing methods for filovirus antibodies.

Authors:  L H Elliott; S P Bauer; G Perez-Oronoz; E S Lloyd
Journal:  J Virol Methods       Date:  1993-06       Impact factor: 2.014

5.  Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978.

Authors:  D L Heymann; J S Weisfeld; P A Webb; K M Johnson; T Cairns; H Berquist
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

6.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

7.  Human asymptomatic Ebola infection and strong inflammatory response.

Authors:  E M Leroy; S Baize; V E Volchkov; S P Fisher-Hoch; M C Georges-Courbot; J Lansoud-Soukate; M Capron; P Debré; J B McCormick; A J Georges
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

8.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

9.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

10.  Novel simian foamy virus infections from multiple monkey species in women from the Democratic Republic of Congo.

Authors:  William M Switzer; Shaohua Tang; Steve Ahuka-Mundeke; Anupama Shankar; Debra L Hanson; HaoQiang Zheng; Ahidjo Ayouba; Nathan D Wolfe; Matthew LeBreton; Cyrille F Djoko; Ubald Tamoufe; Amandine Esteban; Walid Heneine; Martine Peeters; Linda L Wright; Jean Jacques Muyembe-Tamfum; Emile Okitolonda Wemakoy; Prime Mulembakani; Nicole A Hoff; Anne W Rimoin
Journal:  Retrovirology       Date:  2012-12-05       Impact factor: 4.602

View more
  14 in total

1.  Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo.

Authors:  Anna Bratcher; Nicole A Hoff; Reena H Doshi; Adva Gadoth; Megan Halbrook; Patrick Mukadi; Kamy Musene; Benoit Ilunga-Kebela; D'Andre Spencer; Matthew S Bramble; David McIlwan; J Daniel Kelly; Daniel Mukadi; Placide Mbala Kingebeni; Steve Ahuka; Emile Okitolonda-Wemakoy; Jean-Jacques Muyembe-Tamfum; Anne W Rimoin
Journal:  PLoS Negl Trop Dis       Date:  2021-08-12

2.  Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.

Authors:  Rebecca Kahn; Matt Hitchings; Rui Wang; Steven E Bellan; Marc Lipsitch
Journal:  Am J Epidemiol       Date:  2019-02-01       Impact factor: 4.897

3.  Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study.

Authors:  Peter J Halfmann; Amie J Eisfeld; Tokiko Watanabe; Tadashi Maemura; Makoto Yamashita; Satoshi Fukuyama; Tammy Armbrust; Isaiah Rozich; Alhaji N'jai; Gabriele Neumann; Yoshihiro Kawaoka; Foday Sahr
Journal:  PLoS Negl Trop Dis       Date:  2019-08-01

4.  Spillover of ebolaviruses into people in eastern Democratic Republic of Congo prior to the 2018 Ebola virus disease outbreak.

Authors:  Tracey Goldstein; Manjunatha N Belaganahalli; Eddy K Syaluha; Jean-Paul K Lukusa; Denise J Greig; Simon J Anthony; Alexandre Tremeau-Bravard; Riddhi Thakkar; Adrian Caciula; Nischay Mishra; W Ian Lipkin; Jasjeet K Dhanota; Brett R Smith; Victoria M Ontiveros; Nistara Randhawa; Michael Cranfield; Christine K Johnson; Kirsten V Gilardi; Jonna A K Mazet
Journal:  One Health Outlook       Date:  2020-11-04

5.  Assessing the determinants of Ebola virus disease transmission in Baka Community of the Tropical Rainforest of Cameroon.

Authors:  Frankline Sevidzem Wirsiy; Alphonse Um Boock; Jane-Francis Tatah Kihla Akoachere
Journal:  BMC Infect Dis       Date:  2021-04-07       Impact factor: 3.090

6.  Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.

Authors:  Dominic Paquin-Proulx; Bronwyn M Gunn; Aljawharah Alrubayyi; Danielle V Clark; Matthew Creegan; Dohoon Kim; Hannah Kibuuka; Monica Millard; Salim Wakabi; Leigh Anne Eller; Nelson L Michael; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb; Galit Alter; Michael A Eller
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

7.  Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States.

Authors:  Colleen S Kraft; Aneesh K Mehta; Jay B Varkey; G Marshall Lyon; Sharon Vanairsdale; Sonia Bell; Eileen M Burd; Mary Elizabeth Sexton; Leslie Anne Cassidy; Patricia Olinger; Kalpana Rengarajan; Vanessa N Raabe; Emily Davis; Scott Henderson; Paula DesRoches; Yongxian Xu; Mark J Mulligan; Bruce S Ribner
Journal:  Infect Control Hosp Epidemiol       Date:  2020-01-20       Impact factor: 6.520

8.  Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover.

Authors:  Pilot Dovih; Eric D Laing; Yihui Chen; Dolyce H W Low; B R Ansil; Xinglou Yang; Zhengli Shi; Christopher C Broder; Gavin J D Smith; Martin Linster; Uma Ramakrishnan; Ian H Mendenhall
Journal:  PLoS Negl Trop Dis       Date:  2019-10-31

9.  A flexible format LAMP assay for rapid detection of Ebola virus.

Authors:  Laura C Bonney; Robert J Watson; Gillian S Slack; Andrew Bosworth; Nadina I Vasileva Wand; Roger Hewson
Journal:  PLoS Negl Trop Dis       Date:  2020-07-31

10.  Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples.

Authors:  Rebecca Surtees; Daniel Stern; Katharina Ahrens; Nicole Kromarek; Angelika Lander; Petra Kreher; Sabrina Weiss; Roger Hewson; Emma K Punch; John N Barr; Peter T Witkowski; Emmanuel Couacy-Hymann; Andrea Marzi; Brigitte G Dorner; Andreas Kurth
Journal:  PLoS Negl Trop Dis       Date:  2020-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.